IP Library Granted Patent US 12,599,739
Granted Patent B2
US 12,599,739 · App. 17/787,710 · Granted Apr 14, 2026

Patient interface with foam cushion

Inventors: Robin Yew (Singapore, SG); Lik Tze Seet (Singapore, SG); Andrew James Bate (Sydney, AU); Kam Man Law (Sydney, AU)
Assignee: RESMED ASIA PTE. LTD.
A61M16/0622A61M16/0672A61M16/0683A61M2205/3344
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,599,739
App. No.
17/787,710
Granted
Apr 14, 2026
Kind
B2
Abstract

A patient interface is configured to deliver a flow of positive pressure respiratory gas to an entrance of a patients airways. The patient interface includes an elastomeric support wall forming at least part of a plenum chamber configured to receive the flow of positive pressure respiratory gas. The patient interface also includes an elastomeric support flange positioned at an end of the elastomeric support wall and extending radially inward from the support wall. The support flange has a flap portion at a central superior region of the support flange that extends further in the radially inward direction than the rest of the support flange. In addition, a foam cushion is mounted on the support flange. The foam cushion is configured to form a seal with the patients face and includes an attachment surface that is in contact with an outer surface of the support flange.

Claims (65)

1 . A patient interface configured to deliver a flow of positive pressure respiratory gas to an entrance of a patient's airways including at least an entrance of the patient's nares, the patient interface being configured to maintain a therapy pressure in a range of about 4 cmH2O to about 30 cmH2O above ambient pressure in use, throughout the patient's respiratory cycle, while the patient is sleeping, to ameliorate sleep disordered breathing, the patient interface comprising:

an elastomeric support wall forming at least part of a plenum chamber configured to receive the flow of positive pressure respiratory gas, the elastomeric support wall comprising a pair of thickened regions on opposing sides of a plane that bisects the elastomeric support wall and extends from the superior side of the elastomeric support wall to the inferior side of the elastomeric support wall;

an elastomeric support flange positioned at an end of the elastomeric support wall and extending radially inward from the support wall, the support flange comprising a flap portion at a central superior region of the support flange that extends further in the radially inward direction than the rest of the support flange; and

a foam cushion mounted on the support flange, the foam cushion being configured to form a seal with the patient's face and comprising an attachment surface that is in contact with an outer surface of the support flange,

wherein the thickness of the elastomeric support wall is greatest in the pair of thickened regions, and

wherein the increased thickness of the thickened regions of the elastomeric support wall does not extend into the elastomeric support flange.

2 . The patient interface of claim 1 , wherein the attachment surface of the foam cushion is widest at a location corresponding to the flap portion.

3 . The patient interface of according to claim 1 , wherein the outer surface of the support flange at the flap portion has a positive curvature.

4 . The patient interface of claim 3 , wherein a central inferior region of the support flange has a positive curvature.

5 . The patient interface of claim 4 , wherein the curvature of the support flange in the flap portion is larger than the curvature of the support flange in the central inferior region.

6 . The patient interface of claim 1 , wherein the central inferior region of the support flange is between a first pair of negative curvature regions of the support flange.

7 . The patient interface of claim 1 , wherein the flap portion is between a second pair of negative curvature regions of the support flange.

8 . The patient interface of claim 1 , wherein the support flange comprises eight transition regions in which the curvature of the outer surface of the support flange transitions from positive to negative or negative to positive.

9 . The patient interface of claim 1 , wherein the foam cushion comprises a sealing surface configured to be in contact with the patient's face in use, wherein the sealing surface of the foam cushion has a positive curvature at locations where the outer surface of the support flange has a positive curvature, and wherein the sealing surface of the foam cushion has a negative curvature at locations where the outer surface of the support flange has a negative curvature.

10 . The patient interface of claim 1 , wherein the outer surface of the support flange in the flap portion has a saddle shape.

11 . The patient interface of claim 1 , wherein the outer surface of the support flange in the central inferior region has a saddle shape.

12 . The patient interface of claim 1 , wherein the outer surface of the support flange in the flap portion is between a first pair of dome regions.

13 . The patient interface of claim 1 , wherein the outer surface of the support flange in the central inferior region is between a second pair of dome regions.

14 . The patient interface of claim 1 , wherein the foam cushion overhangs the support flange.

15 . The patient interface of claim 1 , further comprising a shell with an inlet opening configured to receive the flow of positive pressure respiratory gas, the support wall being mounted to the shell.

16 . The patient interface of claim 15 , further comprising a positioning and stabilizing structure configured to support the shell, the support wall, and the foam cushion on the patient's head, the positioning and stabilizing structure being removably attachable to the shell.

17 . The patient interface of claim 16 , wherein the positioning and stabilizing structure comprises a shroud and a plurality of headgear straps.

18 . The patient interface of claim 17 , wherein the shroud is removably attachable to the shell at the inlet opening.

19 . The patient interface of claim 18 , further comprising an air delivery tube connectable to the shroud and the shell.

20 . A patient interface configured to deliver a flow of positive pressure respiratory gas to an entrance of a patient's airways including at least an entrance of the patient's nares, the patient interface being configured to maintain a therapy pressure in a range of about 4 cmH2O to about 30 cmH2O above ambient pressure in use, throughout the patient's respiratory cycle, while the patient is sleeping, to ameliorate sleep disordered breathing, the patient interface comprising:

an elastomeric support wall forming at least part of a plenum chamber configured to receive the flow of positive pressure respiratory gas;

an elastomeric support flange positioned at an end of the elastomeric support wall and extending radially inward from the support wall; and

a foam cushion mounted on the support flange, the foam cushion being configured to form a seal with the patient's face,

wherein an elastomeric wall thickness of the support flange varies from a central superior region of the support flange to a central inferior region of the support flange,

wherein the thickness of the elastomeric support wall is greatest in a thickened region, and

wherein the increased thickness of the thickened region of the elastomeric support wall does not extend into the elastomeric support flange.

21 . The patient interface of claim 20 , wherein the elastomeric wall thickness of the support flange is thinner at the central superior region and the central inferior region than in intermediate regions between the central superior region and the central inferior region.

22 . The patient interface of claim 20 , wherein the elastomeric wall thickness of the support flange is thinner at the central superior region than at the central inferior region.

23 . The patient interface of claim 20 , wherein an elastomeric wall thickness of the support wall varies from a central superior region of the support wall to a central inferior region of the support wall.

24 . The patient interface of claim 23 , wherein the elastomeric wall thickness of the support wall is thinner at the central superior region of the support wall and at the central inferior region of the support wall than at intermediate regions between the central superior region and the central inferior region.

25 . The patient interface of claim 23 , wherein the elastomeric wall thickness of the support wall is thinner at the central superior region than at the central inferior region.

26 . The patient interface of claim 20 , wherein the central superior region of the support wall comprises a superior gusset, and the central inferior region of the support wall comprises an inferior gusset.

27 . The patient interface of claim 26 , wherein the inferior gusset is more collapsible than the superior gusset.

28 . The patient interface of claim 20 , wherein a thickness of the foam cushion is consistent throughout the foam cushion.

29 . The patient interface of claim 20 , further comprising a pair of compressible ribs at an inferior region of the patient interface, each of the compressible ribs being attached to the support wall and the support flange and being configured to prevent at least a portion of the support flange from flexing due to positive pressure in the plenum chamber.

30 . The patient interface of claim 20 , wherein the support flange comprises a flap portion at the central superior region of the support flange that extends further in the radially inward direction than the rest of the support flange, and wherein the flap portion is configured to prevent at least a portion of the support flange from flexing due to positive pressure in the plenum chamber.

31 . The patient interface of claim 20 , wherein the foam cushion overhangs the support flange.

32 . The patient interface of claim 20 , wherein the foam cushion comprises an attachment surface configured to be attached to the support flange and comprises a sealing surface configured to contact and form a seal with the patient's face, wherein the foam cushion is bent around a bisecting plane that bisects the foam cushion and extends through the central superior region and the central inferior region of the foam cushion, and wherein the attachment surface and the sealing surface are wider at the bisecting plane than at the remaining portions of the foam cushion.

33 . The patient interface of claim 32 , wherein the foam cushion comprises a perimeter surface extending from the attachment surface to the sealing surface, and wherein the perimeter surface is concave at the central inferior region.

34 . The patient interface of claim 20 , further comprising a shell with an inlet opening configured to receive the flow of positive pressure respiratory gas, the support wall being mounted to the shell.

35 . The patient interface of claim 34 , further comprising a positioning and stabilizing structure configured to support the shell, the support wall, and the foam cushion on the patient's head, the positioning and stabilizing structure being removably attachable to the shell.

36 . The patient interface of claim 35 , wherein the positioning and stabilizing structure comprises a shroud and a plurality of headgear straps.

37 . The patient interface of claim 36 , wherein the shroud is removably attachable to the shell at the inlet opening.

38 . The patient interface of claim 37 , further comprising an air delivery tube connectable to the shroud and the shell.

39 . A patient interface configured to deliver a flow of positive pressure respiratory gas to an entrance of a patient's airways including at least an entrance of the patient's nares, the patient interface being configured to maintain a therapy pressure in a range of about 4 cmH2O to about 30 cmH2O above ambient pressure in use, throughout the patient's respiratory cycle, while the patient is sleeping, to ameliorate sleep disordered breathing, the patient interface comprising:

a shell with an inlet opening configured to receive the flow of positive pressure respiratory gas;

an elastomeric support wall mounted to the shell, the shell and the elastomeric support wall together forming at least part of a plenum chamber configured to receive the flow of positive pressure respiratory gas, the elastomeric support wall comprising a pair of thickened regions on opposing sides of a plane that bisects the elastomeric support wall and extends from the superior side of the elastomeric support wall to the inferior side of the elastomeric support wall;

an elastomeric support flange positioned at an end of the elastomeric support wall and extending radially inward from the support wall; and

a foam cushion mounted on the support flange, the foam cushion being configured to form a seal with the patient's face,

wherein the inlet opening has a central longitudinal axis that extends through an anterior aperture configured to receive the patient's nose, and

wherein the elastomeric support wall and the foam cushion are configured so that when the patient interface is mounted on the patient's face, a part of the central longitudinal axis extending outwardly from the anterior side of the patient interface extends in an inferior direction,

wherein the thickness of the elastomeric support wall is greatest in the pair of thickened regions, and

wherein the increased thickness of the thickened regions of the elastomeric support wall does not extend into the elastomeric support flange.

40 . The patient interface of claim 39 , wherein the support wall is configured to pivot around a lateral axis that extends through lateral sides of the support wall.

41 . The patient interface of claim 40 , wherein an inferior portion of the support wall comprises an inferior gusset, and the inferior gusset is configured so that the support wall flexes around the lateral axis when the inferior gusset is collapsed.

42 . The patient interface of claim 39 , wherein a superior portion of the support wall comprises a superior gusset.

43 . The patient interface of claim 39 , further comprising a positioning and stabilizing structure configured to support the shell, the support wall, and the foam cushion on the patient's head, the positioning and stabilizing structure being removably attachable to the shell.

44 . The patient interface of claim 43 , wherein the positioning and stabilizing structure comprises a shroud and a plurality of headgear straps.

45 . The patient interface of claim 44 , wherein the shroud is removably attachable to the shell at the inlet opening.

46 . The patient interface of claim 45 , further comprising an air delivery tube connectable to the shroud and the shell.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2022
From: BATE, ANDREW JAMES; LAW, KAM MAN
To: RESMED PTY LTD
Reel/Frame 060787/0406 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2022
From: YEW, ROBIN; SEET, LIK TZE
To: RESMED ASIA PTE. LTD.
Reel/Frame 060787/0488 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2022
From: RESMED PTY LTD
To: RESMED ASIA PTE. LTD.
Reel/Frame 060787/0522 →
Continuity (1)
Related Publication 20230039856A1 · Feb 9, 2023
References Cited (168)
US 4782832A · Trimble et al. · 1988 [cited by applicant]
US 4907584A · Mcginnis et al. · 1990 [cited by applicant]
US 4944310A · Sullivan · 1990 [cited by applicant]
US 5687715A · Landis · 1997 [cited by applicant]
US 6397847B1 · Scarberry et al. · 2002 [cited by applicant]
US 6467483B1 · Kopacko · 2002 [cited by examiner]
US 6532959B1 · Berthon-Jones · 2003 [cited by applicant]
US 6581594B1 · Drew et al. · 2003 [cited by applicant]
US 7219670B2 · Jones, Jr. et al. · 2007 [cited by applicant]
US 7866944B2 · Kenyon et al. · 2011 [cited by applicant]
US 8636479B2 · Kenyon et al. · 2014 [cited by applicant]
US 8638014B2 · Sears et al. · 2014 [cited by applicant]
US 8733349B2 · Bath et al. · 2014 [cited by applicant]
US 9132255B2 · Skipper et al. · 2015 [cited by applicant]
US 9320865B2 · Ho · 2016 [cited by applicant]
US 9993606B2 · Gibson et al. · 2018 [cited by applicant]
US 10166357B2 · Veliss et al. · 2019 [cited by applicant]
US 10188820B2 · Edwards · 2019 [cited by applicant]
US 10207070B2 · Bayer et al. · 2019 [cited by applicant]
US 10500362B2 · Henry et al. · 2019 [cited by applicant]
US 11020558B2 · Kwok et al. · 2021 [cited by applicant]
US 11110241B2 · Lockhart et al. · 2021 [cited by applicant]
US 20010020474A1 · Hecker et al. · 2001 [cited by applicant]
US 20030019496A1 · Kopacko et al. · 2003 [cited by applicant]
US 20030196656A1 · Moore et al. · 2003 [cited by applicant]
US 20060096598A1 · Ho et al. · 2006 [cited by applicant]
US 20060130844A1 · Ho et al. · 2006 [cited by applicant]
US 20070044804A1 · Matula, Jr. · 2007 [cited by examiner]
US 20070267017A1 · Mcauley et al. · 2007 [cited by applicant]
US 20080110464A1 · Davidson et al. · 2008 [cited by applicant]
US 20080302366A1 · Mcginnis et al. · 2008 [cited by applicant]
US 20090044808A1 · Guney et al. · 2009 [cited by applicant]
US 20090050156A1 · Ng et al. · 2009 [cited by applicant]
US 20100000534A1 · Kooij et al. · 2010 [cited by applicant]
US 20100006101A1 · Mcauley et al. · 2010 [cited by applicant]
US 20100170516A1 · Grane · 2010 [cited by applicant]
US 20120080035A1 · Guney et al. · 2012 [cited by applicant]
US 20120138062A1 · Ho et al. · 2012 [cited by applicant]
US 20120204879A1 · Cariola et al. · 2012 [cited by applicant]
US 20120222680A1 · Eves et al. · 2012 [cited by applicant]
US 20120285464A1 · Birch et al. · 2012 [cited by applicant]
US 20130139822A1 · Gibson et al. · 2013 [cited by applicant]
US 20130146060A1 · Ho et al. · 2013 [cited by applicant]
US 20130199537A1 · Formica et al. · 2013 [cited by applicant]
US 20130340763A1 · Eifler et al. · 2013 [cited by applicant]
US 20140144448A1 · Eifler · 2014 [cited by applicant]
US 20140174446A1 · Prentice et al. · 2014 [cited by applicant]
US 20140196720A1 · Eury · 2014 [cited by applicant]
US 20140216462A1 · Law · 2014 [cited by examiner]
US 20140326246A1 · Chodkowski et al. · 2014 [cited by applicant]
US 20150040911A1 · Davidson et al. · 2015 [cited by applicant]
US 20150090266A1 · Melidis et al. · 2015 [cited by applicant]
US 20150144140A1 · Eury et al. · 2015 [cited by applicant]
US 20150151067A1 · Eury et al. · 2015 [cited by applicant]
US 20150151071A1 · Von Moger · 2015 [cited by examiner]
US 20150246198A1 · Bearne et al. · 2015 [cited by applicant]
US 20150250971A1 · Bachelder et al. · 2015 [cited by applicant]
US 20150335845A1 · Baiko et al. · 2015 [cited by applicant]
US 20150374944A1 · Edwards · 2015 [cited by applicant]
US 20160001029A1 · Bayer et al. · 2016 [cited by applicant]
US 20160082213A1 · Eifler et al. · 2016 [cited by applicant]
US 20180185598A1 · Olsen et al. · 2018 [cited by applicant]
US 20180256843A1 · Eves et al. · 2018 [cited by applicant]
US 20180256844A1 · Galgali et al. · 2018 [cited by applicant]
US 20180272094A1 · Eves et al. · 2018 [cited by applicant]
US 20180272095A1 · Eves et al. · 2018 [cited by applicant]
US 20180280649A1 · Eves et al. · 2018 [cited by applicant]
US 20190151590A1 · Guney et al. · 2019 [cited by applicant]
US 20200121880A1 · Olsen et al. · 2020 [cited by applicant]
US 20200384230A1 · Eves et al. · 2020 [cited by applicant]
US 20220111171A1 · Eves et al. · 2022 [cited by applicant]
CN 1901962A · 2007 [cited by applicant]
CN 101198379A · 2008 [cited by applicant]
CN 101242866A · 2008 [cited by applicant]
CN 101301505A · 2008 [cited by applicant]
CN 102753230 · 2012 [cited by applicant]
CN 103945890A · 2014 [cited by applicant]
CN 104587580A · 2015 [cited by applicant]
EP 1258266A1 · 2002 [cited by applicant]
EP 1982740A2 · 2008 [cited by applicant]
EP 3095478A1 · 2016 [cited by applicant]
GB 2385533A · 2003 [cited by applicant]
JP 2008518718A · 2008 [cited by applicant]
JP 2012530561 · 2012 [cited by applicant]
JP 2015516241A · 2015 [cited by applicant]
JP 2016504940 · 2016 [cited by applicant]
JP 2017527365 · 2017 [cited by applicant]
JP 2018526154A · 2018 [cited by applicant]
JP 2018527154A · 2018 [cited by applicant]
JP 2019508158 · 2019 [cited by applicant]
WO WO98004310A1 · 1998 [cited by applicant]
WO WO98034665A1 · 1998 [cited by applicant]
WO WO2000078381A1 · 2000 [cited by applicant]
WO WO2004073778A1 · 2004 [cited by applicant]
WO WO2005063328A1 · 2005 [cited by applicant]
WO WO2006074513A1 · 2006 [cited by applicant]
WO WO2006130903A1 · 2006 [cited by applicant]
WO WO2009052560A1 · 2009 [cited by applicant]
WO 2010009877A1 · 2010 [cited by applicant]
WO 2010148453A1 · 2010 [cited by applicant]
WO WO2010135785A1 · 2010 [cited by applicant]
WO WO2012171072A1 · 2012 [cited by applicant]
WO WO2013020167A1 · 2013 [cited by applicant]
WO 2014038959A1 · 2014 [cited by applicant]
WO 2014062070A1 · 2014 [cited by applicant]
WO 2014091360A1 · 2014 [cited by applicant]
WO 2014110626A1 · 2014 [cited by applicant]
WO 2014117227 · 2014 [cited by applicant]
WO 2014155329A2 · 2014 [cited by applicant]
WO 2015009172A1 · 2015 [cited by applicant]
WO 2015063283A1 · 2015 [cited by applicant]
WO 2016032343A1 · 2016 [cited by applicant]
WO 2016041019A1 · 2016 [cited by applicant]
WO 2016054692A2 · 2016 [cited by applicant]
WO 2016149769 · 2016 [cited by applicant]
WO 2017042717A1 · 2017 [cited by applicant]
WO 2017049359 · 2017 [cited by applicant]
WO 2017049359A1 · 2017 [cited by applicant]
WO 2017049360 · 2017 [cited by applicant]
WO 2017049361 · 2017 [cited by applicant]
WO WO2017120643A1 · 2017 [cited by examiner]
WO 2017185140A1 · 2017 [cited by applicant]
WO 2019183680A1 · 2019 [cited by applicant]
WO 2019183681A1 · 2019 [cited by applicant]
Office Action dated May 7, 2025 issued in Japanese Application No. 2024-101976 with English translation (6 pages). [cited by applicant]
Extended European Search Report dated Jun. 17, 2025 issued in European Application No. 24215665.1 (12 pages). [cited by applicant]
Office Action dated Jun. 16, 2025 issued in Chinese Application No. 201980103524.4 with English translation (16 pages). [cited by applicant]
Office Action dated Dec. 11, 2024 issued in Canadian Application No. 3,209,012 (5 pages). [cited by applicant]
Office Action dated Dec. 24, 2024 issued in Chinese Application No. 201980103524.4 with English translation (12 pages). [cited by applicant]
Office Action dated Nov. 14, 2022 issued in Japanese Application No. 2022-537761 with English translation (20 pages). [cited by applicant]
Extended European Search Report dated Jan. 27, 2023 issued in European Application No. 19957007.8 (7 pages). [cited by applicant]
Office Action dated Feb. 21, 2025 issued in Chinese Application No. 201980103524.4 with English translation (18 pages). [cited by applicant]
Examination Report dated Apr. 3, 2025 issued in Australian Application No. 2024204860 (2 pages). [cited by applicant]
Office Action dated Jan. 22, 2024 issued in Japanese Application No. 2023-060822 with English translation (9 pages). [cited by applicant]
[cited by applicant]
International Search Report dated Apr. 16, 2020 issued in International Application No. PCT/IB2019/061217 (6 pages). [cited by applicant]
Written Opinion of the International Searching Authority dated Apr. 16, 2020 issued in International Application No. PCT/IB2019/061217 (6 pages). [cited by applicant]
Written Opinion of the International Searching Authority dated Nov. 15, 2021 issued in International Application No. PCT/IB2019/061217 (6 pages). [cited by applicant]
International Preliminary Report on Patentability dated Mar. 29, 2022 issued in International Application No. PCT/IB2019/061217 (28 pages). [cited by applicant]
Office Action dated Apr. 28, 2021 issued in Chinese Application No. 201680066661.1 with English translation (16 pages). [cited by applicant]
Office Action dated Jun. 28, 2021 issued in Japanese Application No. 2018-533976 with English translation (6 pages). [cited by applicant]
Notice of Allowance dated Jun. 21, 2021 issued in Japanese Application No. 2018-533977 (3 pages). [cited by applicant]
Notice of Allowance dated Jul. 19, 2021 issued in Japanese Application No. 2018-533978 (3 pages). [cited by applicant]
Office Action dated Dec. 8, 2020 issued in Chinese Application No. 201680066661.1 with English translation (11 pages). [cited by applicant]
Office Action dated Oct. 5, 2020 issued in Japanese Application No. 2018-533976 with English translation (8 pages). [cited by applicant]
International Preliminary Report on Patentability for PCT/AU2016/050894, mailed Jan. 16, 2018, 11 pages. [cited by applicant]
Office Action dated Oct. 19, 2020 issued in Japanese Application No. 2018-533978 with English translation (8 pages). [cited by applicant]
Office Action dated Oct. 26, 2020 issued in European Application No. 16847658.8 (5 pages). [cited by applicant]
Notice of Reasons for Rejection dated Oct. 12, 2020 issued in Application No. 2018-533977 with English translation (15 pages). [cited by applicant]
Office Action dated Oct. 15, 2020 issued in European Application No. 16847657.0 (5 pages). [cited by applicant]
Office Action dated Feb. 3, 2020 issued in Chinese Application No. 201680056156.9 with English translation (15 pages). [cited by applicant]
Office Action dated Feb. 3, 2020 issued in Chinese Application No. 201680061003.3 with English translation (21 pages). [cited by applicant]
Office Action dated Jan. 28, 2020 issued in U.S. Appl. No. 15/759,985 (17 pages). [cited by applicant]
Office Action dated Feb. 25, 2020 issued in U.S. Appl. No. 15/761,168 (22 pages). [cited by applicant]
Extended European Search Report dated May 10, 2019 issued in European Application No. 16847657.0 (8 pages). [cited by applicant]
International Search Report for PCT/AU2016/050896, mailed Jan. 3, 2017, 8 pages. [cited by applicant]
Written Opinion for PCT/AU2016/050896, mailed Jan. 3, 2017, 7 pages. [cited by applicant]
Written Opinion of the ISA for PCT/AU2016/050894, mailed Dec. 12, 2016, 4 pages. [cited by applicant]
Written Opinion of the IPEA for PCT/AU2016/050894, mailed Oct. 27, 2017, 6 pages. [cited by applicant]
International Preliminary Report on Patentability for PCT/AU2016/050896, mailed Jan. 9, 2018, 189 pages. [cited by applicant]
International Search Report for PCT/AU2016/050895, mailed Jan. 12, 2017, 15 pages. [cited by applicant]
Written Opinion of the ISA PCT/AU2016/050895, mailed Jan. 12, 2017, 12 pages. [cited by applicant]
Written Opinion of the IPEA for PCT/AU2016/050895, mailed Oct. 23, 2017, 10 pages. [cited by applicant]
International Preliminary Report on Patentability for PCT/AU2016/050895, mailed Jan. 22, 2018, 221 pages. [cited by applicant]
Extended European Search Report dated May 13, 2019 issued in European Application No. 16847658.8 (11 pages). [cited by applicant]
Partial Supplementary European Search Report dated May 13, 2019 issued in European Application No. 16847659.6 (15 pages). [cited by applicant]
International Search Report for PCT/AU2016/050894, mailed Dec. 12, 2016, 7 pages. [cited by applicant]
Chinese Office Action dated Jan. 14, 2026, received in CN Application No. 201980103524.4, 108 pp. [cited by applicant]